Gene changes in beta-thalassemia patients
Part of Blood & lymphatic clinical trials.
This study looks for changes in a specific gene (KLF1) that might be linked to beta-thalassemia. If you have beta-thalassemia, joining could help researchers understand the disease better — and it involves only a blood test for DNA analysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have beta-thalassemia (either the moderate form called intermedia or the severe form called major)
- Any age or gender is okay
- You cannot have other types of hemolytic anemias (conditions where red blood cells break down too quickly)
- You cannot be taking hydroxyurea (a medicine that changes how blood cells are made)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a gene called EKLF in people with beta-thalassemia. It aims to understand how this gene works in the body, which could help improve future treatments.
This trial tests a new gene-editing treatment called CS-101 for people with beta-thalassemia major who need regular blood transfusions. It aims to see if the treatment is safe and can reduce or eliminate the need for transfusions.
This trial tests a new gene therapy that uses a modified virus to add a working copy of the gene for beta globin, which may help your body make healthy red blood cells. It is designed for people with beta thalassemia who have not had a bone marrow transplant and do not have a matching sibling donor.
This trial tests a new gene therapy for people with beta-thalassemia who need regular blood transfusions. It uses a virus to deliver a working gene into your own stem cells, then those cells are put back into your body to help your body make healthy red blood cells.
This trial tests a one-time gene therapy using your own stem cells to help you produce healthy red blood cells and reduce or eliminate the need for regular blood transfusions. It is for people with transfusion-dependent beta-thalassemia who are between 3 and 35 years old.
This trial tests a one-time gene therapy using your own blood stem cells to treat severe beta-thalassemia. It may help you stop needing regular blood transfusions.
Hear when a new EKLF Mutations in Beta Thalassemia Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.